Unraveling the unforeseen: anuric acute kidney injury induced by alectinib.

Introduction: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is pivotal in managing ALK-positive non-small cell lung cancer (NSCLC) due to its efficacy and favorable safety profile. However, severe renal toxicity, including acute kidney injury (AKI), remains a rare but significant adverse effect.

Case Report: We present the case of a 71-year-old female with a history of diabetes and recently diagnosed ALK-positive NSCLC.